PDF factsheet
      Z

antiplatelets drug in post myocardial infarction for all type of patient, clinical trials results

aspirin versus placebo
CDPA, 1976
Aspirin (324 mg) 3x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 1.83 y
USA
Cardiff I, 1974
Aspirin (300 mg) 1x/d
versus
Placebo
MI survivorsDouble blind
Follow-up duration: 2 years
UK
Cardiff II, 1979
Aspirin (300 mg) 3x/d for one year
versus
Placebo
patients with myocardial infarctionDouble blind
Follow-up duration: 1 y
South Wales
Vogel, 1979
Aspirin (1.5 g daily) on an average period of 22 months
versus
Placebo
Double blind
Follow-up duration: 1.75 y (mean)
Germany
AMIS, 1980
NCT00000491
Aspirin (500 mg) 2x/d for at least 3 years
versus
Placebo
men and women who had had a documented myocardial infarctionDouble blind
Follow-up duration: > 3 y
USA
GAMIS, 1980
Aspirin (500 mg) 3x/d for 2 years
versus
Placebo
patients who had survived a myocardial infarction for 30-42 days Double blind
Follow-up duration: 2 y
Germany, Austria,
PARIS, 1980
Aspirin (324 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 mo
USA, UK
JAMIS, 1999
Aspirin (81 mg) 1x/d
versus
No antiplatelets
patients with AMI within 1 month from the onset of symptomsOpen
Follow-up duration: 1.3 y (mean)
Japan
clopidogrel versus aspirin
CAPRIE, 1996
Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years
versus
Aspirin (325 mg) 1x/d
patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial diseaseDouble blind
Follow-up duration: 1.91 y
16 countries (USA, Canada, Europe, Australia and NZ
dipyridamol + aspirin versus aspirin
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Aspirin (324 mg) 3x/d
patuents who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months
USA and GB
dipyridamol + aspirin versus placebo
PARIS, 1980
Aspirin (324 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction Double blind
Follow-up duration: 41 months (mean)
USA and UK
PARIS-II, 1986
Aspirin (330 mg) + dipyridamole (75 mg) 3x/d
versus
Placebo
patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previouslyDouble blind
Follow-up duration: 23.4 months
USA and UK
ticagrelor versus placebo (on top aspirin)
PEGASUS 60mg, 2015
NCT01225562
ticagrelor at a dose of 60 mg twice daily
versus
placebo
patients who had had a myocardial infarction 1 to 3 years earlierdouble-blind
Follow-up duration: 2.75 y (median)
PEGASUS 90mg, 2015
NCT01225562
ticagrelor at a dose of 90 mg twice daily
versus
patients who had had a myocardial infarction 1 to 3 years earlier double-blind
Follow-up duration: 2.75 y (median)
vorapaxar versus placebo (on top aspirin)
TRA-2P TIMI 50, 2012
NCT00526474
vorapaxar (SCH 530348) 2.5-mg daily
versus
placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)double-blind
Follow-up duration: 2.5 y (median)

  Options


in first

in second

  Filter